SYK logo

STRYKER CORP

SYKNYSE
πŸ† #122 by market capEarnings Oct 29 Β· PostUS Equity
$304.17β–² $2.74 (+0.91%)
After hours Β· at close
πŸ””
Track SYK
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.9%
7dβ–² 2.3%
14dβ–² 8.0%
30dβ–² 10.4%
ytdβ–Ό 13.4%
1yβ–Ό 19.1%
🏦Market Cap
$116.67B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
8.5%
Slowing
πŸ“ŠGross Margin
65.3%
High
πŸ’΅FCF Margin
18.2%
Healthy
βš–οΈP/S Ratio
4.5x
Fair
Otter Score
80
Strong

Trading Snapshot

Day Range
$297.98 – $305.25
52-Week Range
$267.00 – $389.33
Volume (shares)
92,840
Avg Volume (shares)
β€”
Shares Outstanding
383.6M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$25.12B
Last Q Revenue
$6.59B
P/E Ratio
31.4
P/S Ratio
4.5x
EPS (TTM)
$9.65
Dividend Yield
1.13%
Dilution (1yr)
+0.1%
SYK logo

STRYKER CORP

SYK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$25.1Bβ–² +11.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.0%β–Ό βˆ’0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$4.9Bβ–² +32.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$4.3Bβ–² +22.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
386.5Mβ–² +0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$12.3Bβ–Ό βˆ’$1.9B YoY
StockOtter Β· stockotter.space

About STRYKER CORP

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100

Analyst Ratings

β“˜
Consensus
Buy
33 analysts
Strong Buy12
Buy15
Hold6
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.